Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | PAK3 | O75914 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.36 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338993 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL338673 | 0.90 | DPP4 (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL1911464 | 0.88 | DPP4 (0.35) | DPP4DPP8DPP9 | |
| SCHEMBL338626 | 0.80 | DPP4 (0.45) | DPP4DPP8DPP9 | |
| SCHEMBL339960 | 0.79 | DPP4 (0.44) | DPP4DPP8DPP9SOS1 | |
| SCHEMBL339026 | 0.78 | DPP4 (0.46) | DPP4DPP8DPP9 | |
| SCHEMBL338998 | 0.76 | PIK3CA (0.41) | DPP4SOS1 | |
| SCHEMBL338266 | 0.74 | DPP4 (0.44) | DPP4DPP8 | |
| SCHEMBL1912415 | 0.74 | CRHR1 (0.36) | DPP4DPP8DPP9 | |
| SCHEMBL339388 | 0.73 | DPP4 (0.43) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | DPP4 120/4885HRH4 2744/4885PAK3 4762/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | DPP4 120/4885HRH4 2744/4885PAK3 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.